Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline announces new investment in UK manufacturing

GlaxoSmithKline announces new investment in UK manufacturing

27th July 2016

GlaxoSmithKline has announced that it will be spending 275 million pounds to bolster production at three of its manufacturing sites in the UK.

The company is seeking to expand its sites in Barnard Castle, County Durham, in Montrose, Scotland and in Ware, Hertfordshire, in order to support delivery of its latest innovative respiratory and large molecule biological medicines.

At Barnard Castle, 92 million pounds will be spent to fund the construction of an aseptic sterile facility, with 110 million pounds going to Montrose to provide a state-of-the-art facility for the manufacture of respiratory active ingredients.

The remaining 74 million pounds will support further expansion of the company's new Ellipta respiratory inhaler through additional manufacturing capacity at the site in Ware.

Andrew Witty, chief executive officer of GlaxoSmithKline, said: "Today's announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly-launched products."

Each of these projects will help to create additional jobs and are indicative of the company's continued commitment to the UK in the wake of the decision to leave the European Union.ADNFCR-8000103-ID-801822554-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.